These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30553471)

  • 1. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
    Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
    Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
    Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
    Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Shimoda K; Takahashi N; Kirito K; Iriyama N; Kawaguchi T; Kizaki M
    Int J Hematol; 2020 Sep; 112(3):268-291. PubMed ID: 32783166
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Bochicchio MT; Marconi G; Baldazzi C; Bandini L; Ruggieri F; Lucchesi A; Agostinelli C; Sabattini E; Orsatti A; Ferrari A; Capirossi G; Servili C; Ghelli Luserna di Rorà A; Martinelli G; Simonetti G; Rosti G
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203288
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.
    Van Limbergen H; Beverloo HB; van Drunen E; Janssens A; Hählen K; Poppe B; Van Roy N; Marynen P; De Paepe A; Slater R; Speleman F
    Genes Chromosomes Cancer; 2001 Mar; 30(3):274-82. PubMed ID: 11170285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.
    Lukes J; Potuckova E; Sramkova L; Stary J; Starkova J; Trka J; Votava F; Zuna J; Zaliova M
    Genes Chromosomes Cancer; 2018 Sep; 57(9):471-477. PubMed ID: 29726059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
    Gniot M; Wasilewska EM; Lewandowski K
    Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.
    Cerrano M; Crisà E; Gottardi E; Aguzzi C; Boccadoro M; Ferrero D
    Am J Hematol; 2016 Sep; 91(9):E353. PubMed ID: 27194679
    [No Abstract]   [Full Text] [Related]  

  • 14. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
    Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
    Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
    Xue S; Sun HP; Huang XB; Chen X; Wang T; Ma W; Tian Y; Pan ZL; Li LH; Zhang L; Liu HX; Cao XY
    Int J Hematol; 2024 May; 119(5):564-572. PubMed ID: 38441775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
    Togitani K; Asagiri T; Kamioka M; Kojima K
    Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant of ETV6/ABL1 gene is associated with leukemia phenotype.
    Park J; Kim M; Lim J; Kim Y; Han K; Kim JS; Lee S; Kim HJ; Min WS
    Acta Haematol; 2013; 129(2):78-82. PubMed ID: 23171811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel ETV6 truncated fusion gene in myeloproliferative neoplasm, unclassifiable with t(4;12)(q12;p13).
    Zhang L; Wang M; Wang Z; Zeng Z; Wen L; Xu Y; Yao L; Cen J; Li H; Pan J; Sun A; Wu D; Chen S; Ma L; Yang X
    Ann Hematol; 2020 Oct; 99(10):2445-2447. PubMed ID: 32734549
    [No Abstract]   [Full Text] [Related]  

  • 20. Myeloproliferative Neoplasm Driven by
    Renzi S; Algawahmed F; Davidson S; Langenberg KPS; Fuligni F; Ali S; Anderson N; Brunga L; Bartram J; Abdelhaleem M; Naqvi A; Beimnet K; Schuh A; Tierens A; Malkin D; Shlien A; Shago M; Villani A
    Curr Oncol; 2023 Jun; 30(7):5946-5952. PubMed ID: 37503586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.